VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Aditi Kumar on Aggressive Multimodal Therapy in Anaplastic Thyroid Cancer

Aditi Kumar, MD
Published: Wednesday, Oct 21, 2015



Aditi Kumar, MD, endocrinology fellow, University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer.

A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

The patients in this trial were treated with surgery if it was possible, intensity modulated radiation therapy, and chemotherapy. This combination of treatment resulted in 22.4 months median overall survival (OS), compared to 5 months median OS with standard of care. One-year survival was 61%.

Toxicities with this aggressive treatment were significant, so patients should be included in discussions concerning treatment requirements and risks, says Kumar.

<<< View more from the 2015 International Thyroid Congress



Aditi Kumar, MD, endocrinology fellow, University of Mississippi, discusses aggressive multimodal therapy in anaplastic thyroid cancer.

A study conducted at the Mayo Clinic, where Kumar was previously a fellow, looked at 29 patients with stage IV, A, B and C anaplastic thyroid cancer, a rare form of thyroid cancer with poor outcomes. Often, patients are not treated at this stage, as options are limited and toxicities from treatments can be high, says Kumar.

The patients in this trial were treated with surgery if it was possible, intensity modulated radiation therapy, and chemotherapy. This combination of treatment resulted in 22.4 months median overall survival (OS), compared to 5 months median OS with standard of care. One-year survival was 61%.

Toxicities with this aggressive treatment were significant, so patients should be included in discussions concerning treatment requirements and risks, says Kumar.

<<< View more from the 2015 International Thyroid Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x